Cidara Therapeutics to Present New Data at ASH 2018 Highlighting Potential of Rezafungin to Prevent Invasive Fungal Infections in Bone Marrow Transplant Patients
The rezafungin ASH abstract (2071),
titled “Pharmacokinetic-Pharmacodynamic Analyses to Provide Rezafungin
Prophylaxis Dose Selection for Prevention of Invasive Fungal Infections
for Bone Marrow Transplant Patients," will be presented in a poster
session on
“The data we will present at ASH are important because they provide
further support that a once-weekly dosing regimen of rezafungin can help
to prevent life-threatening fungal infections in high-risk patients,”
said
Rezafungin is a novel antifungal echinocandin being developed as a once-weekly therapy for the treatment and prevention of serious invasive fungal infections. Rezafungin is being developed to address unmet needs in the treatment of candidemia and invasive candidiasis as well as for prophylaxis of invasive fungal infections due to the common fungal pathogens Candida, Aspergillus and Pneumocystis. Cidara plans to start the Phase 3 ReSPECT prophylaxis clinical trial of rezafungin in patients undergoing allogeneic bone marrow transplantation in the first quarter of 2019.
About Invasive Fungal Infections
Approximately 97,000 Americans die from hospital-related invasive fungal infections each year and 90 percent of these infections are caused by two common fungi, Candida and Aspergillus. Pneumocystis Pneumonia (PCP) is another serious fungal infection that commonly afflicts people with weakened immune systems. Systemic fungal infections typically affect patients whose immune systems have been compromised, such as patients undergoing organ or bone marrow transplantation or chemotherapy, including patients with hematologic malignancies, or patients in intensive care units and those with prolonged hospital stays.
About
Cidara is a clinical-stage biotechnology company focused on developing
new anti-infectives that have the potential to transform the standard of
care and save or improve patients’ lives. The company is currently
advancing its novel echinocandin antifungal, rezafungin acetate, in a
Phase 3 clinical trial in the treatment of candidemia and invasive
candidiasis and plans to initiate a second Phase 3 trial in the
prophylaxis of invasive fungal infections. Rezafungin has improved
pharmacokinetics compared to existing echinocandins and the potential
for expanded utility across patient settings. It is the only once-weekly
product candidate in development for the treatment and prevention of
life-threatening invasive fungal infections. Cidara also is leveraging
its novel Cloudbreak™ platform to develop antibody-drug conjugates for
the treatment of serious viral and Gram-negative bacterial infections.
Cloudbreak is the first immunotherapy discovery platform designed
specifically to create compounds that directly kill pathogens and also
direct a patient’s immune cells to attack and eliminate bacterial,
fungal or viral pathogens. Cidara is headquartered in
Forward-Looking Statements
Statements contained in this press release regarding matters that are
not historical facts are "forward-looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995. Because such
statements are subject to risks and uncertainties, actual results may
differ materially from those expressed or implied by such
forward-looking statements. Such statements include, but are not limited
to, statements regarding the potential for rezafungin to be a novel
treatment and prophylactic agent against deadly invasive fungal
infections, statements regarding the potential for expanded utility
across patient settings, such as immunocompromised patients, as well as
statements regarding rezafungin’s ability to mitigate the challenges
typically associated with prophylaxis of invasive fungal infections in
immunocompromised and bone marrow transplant patients, and statements
regarding the time of initiation of rezafungin Phase 3 pivotal trials.
Risks that contribute to the uncertain nature of the forward-looking
statements include: the success and timing of Cidara’s preclinical
studies and clinical trials; regulatory developments in
View source version on businesswire.com: https://www.businesswire.com/news/home/20181127005460/en/
Source:
INVESTOR CONTACT:
Robert H. Uhl
Westwicke Partners, LLC
Managing
Director
(858) 356-5932
robert.uhl@westwicke.com
MEDIA CONTACT:
Christy Curran
Sam Brown Inc.
615-414-8668
ChristyCurran@sambrown.com